| Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. | |
| | |
MedLine Citation:
|
PMID: 18219445 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: ZD6126 is a novel vascular-targeting agent that disrupts the endothelial tubulin cytoskeleton causing selective occlusion of tumor vasculature and extensive tumor necrosis. This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126. METHODS: Adult patients with solid tumors refractory to existing treatments received a 10-min, single-dose intravenous infusion of ZD6126 every 14 or 21 days. Subsequent dose escalation was performed, based on the incidence of adverse events (AEs) within the first cycle of drug administration. Blood samples were obtained for pharmacokinetic analysis, and the effects of ZD6126 on tumor vasculature were visualized using DCE-MRI technology. RESULTS: Forty-four patients received ZD6126 (5-112 mg/m2 in the 21-day schedule, n=35; 40-80 mg/m2 in the 14-day schedule, n=9). Common AEs were similar in both groups and included abdominal pain, nausea and vomiting, which appeared to be dose related. The incidence of abdominal pain at 112 mg/m2 in the 21-day study prevented further dose escalation. Pharmacokinetic studies confirmed that ZD6126 is rapidly hydrolyzed to ZD6126 phenol. There was no difference in the pharmacokinetics of ZD6126 phenol upon repeat administration or between the two dosing regimens. DCE-MRI evaluation has demonstrated the antivascular effects of ZD6126. CONCLUSIONS: This study identified that ZD6126 administered every 2 or 3 weeks at 80 mg/m2 was well tolerated, with mild but manageable gastrointestinal AEs. In approximately 11% (5 out of 44) of patients, ZD6126 was associated with cardiac events categorized as dose limiting toxicities (one patient with asymptomatic decreased left ventricular ejection fraction (LVEF), two with increased troponin concentrations, one with myocardial ischemia, and one with ECG signs of myocardial ischemia). |
| | |
Authors:
|
Patricia M LoRusso; Shirish M Gadgeel; Antoinette Wozniak; Alan J Barge; Helen K Jones; Zachary S DelProposto; Pamela A DeLuca; Jeffrey L Evelhoch; Scott A Boerner; Catherine Wheeler |
Related Documents
:
|
10577855 - Phase ii study of oral platinum drug jm216 as first-line treatment in patients with sma... 8262735 - Phase ii trial of amonafide in advanced pancreas cancer. a southwest oncology group study. 11313175 - Randomised phase ii trial of pegylated liposomal doxorubicin (doxil/caelyx) versus doxo... 22045445 - Adjuvant therapy for early colon cancer: current status. 19542665 - Results of combined modality treatment for nasopharyngeal cancer. 88495 - Concept of cytostatic therapy in advanced tumours of the head and neck. |
Publication Detail:
|
Type: Clinical Trial, Phase I; Journal Article Date: 2008-01-25 |
Journal Detail:
|
Title: Investigational new drugs Volume: 26 ISSN: 0167-6997 ISO Abbreviation: Invest New Drugs Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-03-10 Completed Date: 2008-07-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309330 Medline TA: Invest New Drugs Country: United States |
Other Details:
|
Languages: eng Pagination: 159-67 Citation Subset: IM |
Affiliation:
|
Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code: HW04HO, Detroit, MI 48201, USA. lorussop@karmanos.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / administration & dosage*, adverse effects, pharmacokinetics Dose-Response Relationship, Drug Endothelium, Vascular / drug effects Female Humans Infusions, Intravenous Magnetic Resonance Imaging Male Middle Aged Neoplasms / drug therapy* Organophosphorus Compounds / administration & dosage*, adverse effects, pharmacokinetics Tubulin / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/N-acetylcochinol-O-phosphate; 0/Organophosphorus Compounds; 0/Tubulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Burning mouth syndrome responsive to pramipexol.
Next Document: A comprehensive analysis of the thermodynamic events involved in ligand-receptor binding using CoRIA...